Product Description
PPV-06 immunotherapy targets interleukin-6 (IL-6), a key molecule of the immune system whose overproduction is involved in many inflammatory and autoimmune diseases.
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Peptinov
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: Czech Republic, Denmark, France, Poland, Romania
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Osteoarthritis, Knee
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PPV-06-KOA-201 | P2 |
Not yet recruiting |
Osteoarthritis, Knee |
2027-12-01 |
|
PPV-06-KOA-201 | P2 |
Unknown Status |
Osteoarthritis, Knee |
2027-09-01 |
|
PPV06-01 | P1 |
Completed |
Osteoarthritis, Knee |
2023-02-28 |
21% |